Industry groups have worked to release guidance on artificial intelligence-backed agents in the absence of federal regulation.
AMA releases governance framework for agentic AI in healthcare Read More »
The results come as Dexcom is awaiting a decision from the Centers for Medicare and Medicaid Services to expand Medicare coverage of the devices for people with Type 2 diabetes.
NEJM study supports CGM use for people with diabetes who don’t take insulin Read More »
In this webinar, BioSpace will gathered experts to discuss China’s impact on the future of biotech and how both U.S. and Chinese companies can thrive—and maybe even collaborate.
Webinar: The China question: Can US biotechs lead as investment heads east? Read More »
AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, following the Phase 3 failure of its Ionis-partnered Wainua in transthyretin-mediated amyloid cardiomyopathy.
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro Read More »
El video póker multimano combina elementos tanto de las tragamonedas como del póker tradicional, pero en la práctica funciona bajo reglas bastante distintas a ambos juegos por separado. En lugar de depender completamente del azar como lo hace una tragamoneda estándar, est …
Qué hace distinto al video póker multimano frente a las tragamonedas tradicionales Read More »
While Oppenheimer doesn’t see the Phase 3 stumble of VQW-765 as highly detrimental to Vanda Pharmaceuticals, the analyst nevertheless believes the stakes are now higher for the company’s planned Q4 readout for Nereus in GLP-1-induced vomiting.
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment Read More »
Arrowhead Pharmaceuticals’ siRNA candidate achieved “compelling” tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperformother blood-brain barrier platforms, according to Stifel.
A new biotech co-founded by Paul Stoffels has formed to take on the CAR T cell assets of Galapagos almost a year after the company—now known as Lakefront Biotherapeutics—abandoned them.
Stoffels strikes up new biotech in return to Galapagos cell therapy mission Read More »
Following several recent initiatives, the FDA’s newest rare disease framework sets out to standardize the agency’s approach to scientific evidence and bring rare disease therapies to patients faster.
FDA’s latest rare disease framework seeks to prioritize consistency in flexibility Read More »
In this episode of Denatured, presented by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we explore how biopharma’s real bottleneck isn’t too little data—it’s too little confidence in the decisions that drive development, manufacturing and commercialization.
